Crescent Biopharma Inc. Common Stock (CBIO)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable competitive advantages, consistent earning power, and a price that offers a margin of safety. Crescent Biopharma does not meet most of those tests today. It is a clinical-stage oncology company with CR-001 in Phase 3, two earlier candidates, a partnership with Sichuan Kelun-Biotech, and just 69 employees. In fiscal 2025, the year ended 2025-12-31, it reported revenue of $10.8 million and a net loss of $153.9 million. In fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was $24.8 million; in fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $1.0 million and the net loss was $23.3 million. Those are not profits I can value. Trailing twelve-month free cash flow was negative $153.6 million, a FairStock calculation, and the FairStock FCF yield was -32.0%. Reported debt is low-D/E 0.01-but cash burn is the real risk. FairStock's Piotroski score is 2/9 and its FairStock Score is 20/100. Its Altman Z-Score of 13.68, as calculated by FairStock, is distorted by the absence of earnings and should not be read as safety. At the 2026-10-13 close of $12.91, market cap was $479.5 million. FairStock calculates P/B of 2.71 and P/E of -92.21. This is not a Graham bargain; it is a speculative bet on clinical data. Until approval, revenue, and a path to profit appear, the price may be fair only as an option on future success, not as an investment in present value.

In plain English: Crescent Biopharma is a small cancer-therapy company that is testing drugs rather than selling profitable products. It has lost money for years, and the latest filings show large losses, so the business looks weak today. At $12.91 a share, the price does not look cheap on current numbers because there is no profit to support it; it reflects hope for future drug trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-Q (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer